Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6171248 | 0.92 | F10 (0.43) | F10F2ELANE | |
| SCHEMBL6170090 | 0.91 | F10 (0.41) | F10F2ELANE | |
| SCHEMBL7082624 | 0.91 | F10 (0.45) | F10RXFP1F2ELANE | |
| SCHEMBL6171175 | 0.89 | F10 (0.46) | F10MAPTRXFP1 | |
| SCHEMBL6168512 | 0.87 | F10 (0.45) | F10F2ELANE | |
| SCHEMBL6168757 | 0.85 | F10 (0.43) | F10F2ELANE | |
| SCHEMBL6169760 | 0.85 | F10 (0.48) | F10MAPTRXFP1F2ELANE | |
| SCHEMBL7372221 | 0.83 | F10 (0.39) | F10RXFP1F2ELANE | |
| SCHEMBL6169049 | 0.81 | F10 (0.38) | F10 | |
| SCHEMBL6168830 | 0.81 | F10 (0.36) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1019045-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20030078431-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2003-04-24 | — | — | US | disclosed |
| US-6500851-B2 | ANTICOAGULANT IN MAMMLS | ELI LILLY AND COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-20020173518-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-11-21 | — | — | US | disclosed |
| US-6372759-B1 | BLOOD COAGULATION FACTOR XA FOR MAMMALS | ELI LILLY AND COMPANY | 2002-04-16 | — | — | US | disclosed |
| WO-1999000128-A9 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173518-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | F10 15/4885MAPT 4730/4885RXFP1 595/4885 |
| US-20030078431-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | F10 15/4885MAPT 4730/4885RXFP1 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.